Anne Marie Kersemaekers

Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial

Kater, A. P., Arslan, Ö., Demirkan, F., Herishanu, Y., Ferhanoglu, B., Diaz, M. G., Leber, B., Montillo, M., Panayiotidis, P., Rossi, D., Skarbnik, A., Tempescul, A., Turgut, M., Mellink, C. H., van der Kevie-Kersemaekers, A-M. F., Lanham, S., Sale, B., del Rio, L., Popovic, R., Chyla, B. J., & 7 othersBusman, T., Komlosi, V., Wang, X., Sail, K., Pena, G. E., Vizkelety, T. & Forconi, F., 1 Apr 2024, In: The Lancet Oncology. 25, 4, p. 463-473 11 p.

Research output: Contribution to journal › Article › Academic › peer-review

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

HOVON CLL Working Group, 28 Sept 2023, In: Blood. 142, 13, p. 1131-1142 12 p.

Research output: Contribution to journal › Article › Academic › peer-review

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Fürstenau, M., Thus, Y. J., Robrecht, S., Mellink, C. H. M., van der Kevie-Kersemaekers, A. M., Dubois, J., von Tresckow, J., Patz, M., Gregor, M., Thornton, P., Staber, P. B., Tadmor, T., Levin, M. D., da Cunha-Bang, C., Schneider, C., Poulsen, C. B., Illmer, T., Schöttker, B., Janssens, A., Christiansen, I., & 27 othersNösslinger, T., Baumann, M., Hebart, H., Gaska, T., Regelink, J. C., Dompeling, E. C., Lindström, V., Juliusson, G., Widmer, A., Goede, J., Goldschmidt, N., Simon, F., De Silva, N., Fink, A. M., Fischer, K., Wendtner, C. M., Ritgen, M., Brüggemann, M., Tausch, E., Spaargaren, M., Eldering, E., Stilgenbauer, S., Niemann, C. U., Hallek, M., Eichhorst, B., Kreuzer, K. A. & Kater, A. P., 3 Aug 2023, In: Blood. 142, 5, p. 446-459 14 p.

Research output: Contribution to journal › Article › Academic › peer-review